NUCLEOLIN and age-related macular degeneration: For example, mucagen, the first aptamer-based drug towards age-related macular degeneration (AMD), is available on market, and some other aptamers such as aptamer AS1411, which is specific for nucleolin, are in clinical trials now [17].